REPROCELL
Daisuke Usui is an accomplished executive with extensive leadership experience in the biotechnology and medical sectors. Currently serving as Chief Operating Officer and Chief Commercial Officer in the USA and EMEA at REPROCELL since June 2016, Daisuke Usui also holds the position of Chief Executive Officer at BioServe, a REPROCELL company, since September 2022. Previous roles include Chief Executive Officer at Reinnervate Ltd and Business Development at REPROCELL in late 2015, along with significant experience at Hoya Surgical Optics and Hoya Medical India Pvt Ltd, where Daisuke Usui held the positions of Director Distributor Sales and Managing Director, respectively. Educational qualifications include a degree from the University of Tsukuba.
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.